Cardurion Pharmaceuticals

Cardurion is a Boston-based cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. In July, 2017, Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced the creation of a new preclinical partnership to develop novel, next-generation therapeutics for the treatment of heart failure and cardiovascular diseases. The partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists in an entrepreneurial setting and enables the Discovery programs of Cardurion.

In April 2018, Cardurion announced the Company entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. With recent evidence supporting that inhibition of PDE-9 has potential to restore heart-protective mechanisms that are dysfunctional in heart failure, CRD-733 has the potential to address the cell-signaling breakdown that contributes to the progression of heart failure.

Cardurion Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $57.9B in funding across 96 round(s). With a team of 11-50 employees, Cardurion Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Cardurion Pharmaceuticals, raised $260.0M. Discover more about their projects, partnerships, and impact on our platform.